Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial-Reference-Cited by-同舟云学术

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Published:2012-01 Issue:1 Volume:13 Page:100-110
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Wheeler Cosette M,Castellsagué Xavier,Garland Suzanne M,Szarewski Anne,Paavonen Jorma,Naud Paulo,Salmerón Jorge,Chow Song-Nan,Apter Dan,Kitchener Henry,Teixeira Júlio C,Skinner S Rachel,Jaisamrarn Unnop,Limson Genara,Romanowski Barbara,Aoki Fred Y,Schwarz Tino F,Poppe Willy A J,Bosch F Xavier,Harper Diane M,Huh Warner,Hardt Karin,Zahaf Toufik,Descamps Dominique,Struyf Frank,Dubin Gary,Lehtinen Matti

Publisher

Elsevier BV

Subject

Oncology

Reference39 articles.

1. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide;Walboomers;J Pathol,1999

2. Epidemiologic classification of human papillomavirus types associated with cervical cancer;Muñoz;N Engl J Med,2003

3. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study;de Sanjosé;Lancet Oncol,2010

4. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline;Schiffman;Infect Agent Cancer,2009

5. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication;Li;Int J Cancer,2011

Cited by 413 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects?;Vaccine;2024-10

2. Effectiveness of HPV vaccine as part of national immunization program for preventing HPV infection in Thai schoolgirls after seven years post-vaccination;Human Vaccines & Immunotherapeutics;2024-09-06

3. Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study;npj Vaccines;2024-08-13

4. Prevalence and genotype distribution of HPV combined with cervical pathological results in women from Sichuan, China: A cross‐sectional study based on post‐vaccination period 2019 to 2023;Cancer Medicine;2024-08

5. IDENTIFYING PLAUSIBLE RANGES FOR DIFFERENTIAL VACCINE EFFICACY ACROSS HIGH- AND LOW-INCOME SETTINGS: A SYSTEMATIC REVIEW, DESCRIPTIVE META-ANALYSIS, AND ILLUSTRATIVE EVIDENCE ANALYSIS;2024-08-01